Drug intelligence / Profile preview

L-VA

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

L-VA is a combination drug regimen primarily investigated for the eradication of Helicobacter pylori (Hp) infection. It consists of vonoprazan, a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion, and amoxicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. The "L" in L-VA specifically denotes a low-dose amoxicillin component, with dosages varying across studies (e.g., 1g three times daily, 1g twice daily, or 500mg four times daily). Clinical trials have evaluated its efficacy and safety in treating Hp infection.

Other names: vonoprazan-based high dose dual therapy

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on L-VA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-VA.

Explore the full profile